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Introduction
Phosphorylation of proteins on serine/threonine residues
preceding proline (Ser/Thr-Pro) is a key signaling mecha-
nism in breast development and breast cancer [1–3]. For
example, activation of oncogenic HER2/Neu/ErbB2
and/or Ras signaling leads to activation of various Pro-
directed protein kinases, which eventually enhance the
transcription of the cyclin D1 gene via multiple transcrip-
tion factors, including E2F, c-Jun/AP-1, and β-catenin/TCF
[4–8]. Furthermore, the function of cyclin D1 itself is regu-
lated by Pro-directed phosphorylation [9–11]. Even the
events downstream from cyclin D1 are also controlled by
Pro-directed phosphorylation, since cyclin D1 is a critical
regulator of G1/S cyclin-dependent protein kinases, which
phosphorylate only certain Ser/Thr-Pro motifs. The role of
cyclin D1 in breast development and cancer has been well
established. Notably, this protein is overexpressed in
human breast cancer [12,13] and such overexpression
can transform cells in vitro [11,14] and cause mammary
hyperplasia and eventually adenocarcinomas in vivo [15].
In contrast, disruption of the cyclin D1 gene in mice sup-
presses massive proliferation of mammary epithelial cells
during pregnancy and prevents Ha-Ras or c-Neu/HER2
from inducing breast cancer [16]. These and other results
indicate that a key regulatory mechanism in breast devel-
opment and cancer is Pro-directed phosphorylation.
Although Ser/Thr phosphorylation has long been believed
to regulate the function of proteins by altering their confor-
mation, little has been known about the actual conforma-
tional changes and their importance until recently.
Recent identification of the new isomerase Pin1 that
specifically isomerizes only the phosphorylated Ser/Thr-
Pro bonds in certain proteins has led to the discovery of a
new signaling mechanism, where prolyl isomerization cat-
alytically induces conformational changes in proteins after
phosphorylation to regulate protein function [17–19]. The
human Pin1 gene was originally identified in a yeast
genetic screen searching for proteins involved in mitotic
regulation and was shown to be the first peptidylproline
cis–trans isomerase (PPIase) that is essential for cell divi-
sion in yeast and human cells [17]. PPIases catalyze the
intrinsically rather slow cis–trans isomerization of peptide
bonds N-terminal of proline residues and play a role in
protein folding or refolding [3,20–22]. The two most well
characterized families of PPIases are the cyclophilins and
FK506-binding proteins (FKBPs), which are involved in
various cell processes. Their best-known function is in the
immune system, where they act as cellular receptors for
the clinically relevant immunosuppressive drugs. However,
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Abstract
The prolyl isomerase Pin1 specifically isomerizes certain phosphorylated Ser/Thr-Pro bonds and
thereby regulates various cellular processes. Pin1 is a target of several oncogenic pathways and is
overexpressed in human breast cancer. Its overexpression can lead to upregulation of cyclin D1 and
transformation of breast epithelial cells in collaboration with the oncogenic pathways. In contrast,
inhibition of Pin1 can suppress the transformation of breast epithelial cells. In addition, Pin1 knockout
in mice prevents massive proliferation of breast epithelial cells during pregnancy. Pin1 plays a pivotal
role in breast development and may be a promising new anticancer target.
Keywords: breast cancer, breast development, cyclin D1, Pin1, phosphorylation signaling77
Available online http://breast-cancer-research.com/content/5/2/76
the PPIase activity of these proteins is neither responsible
for the drug action in the immune system nor essential for
cell survival in yeast [20–22]. Therefore, evidence for the
biological and/or pathological importance of PPIase activ-
ity in these proteins has been elusive.
In contrast to all other characterized PPIases, Pin1 has a
unique substrate specificity: it binds and isomerizes spe-
cific Ser/Thr-Pro motifs only after phosphorylation and
thereby induces conformational changes to regulate the
function of the Pin1 substrates [3,17–19]. Depending on
the substrate protein, these conformational changes can
affect enzymatic activity, phosphorylation status, protein–
protein interactions, subcellular localization, or protein sta-
bility [3,23–29]. Functionally, Pin1-catalyzed prolyl isomer-
ization regulates such complex processes as cell cycle
progression [17,23,24,28,30–37], transcription [34–44],
and the response to DNA damage [45–47]. Furthermore,
Pin1 has been shown to be involved in the pathogenesis
of some human diseases, such as Alzheimer’s disease
[26] and cancer [34–37].
Comprehensive recent reviews on the function and regula-
tion of Pin1 [3,27,48] and on its role in transcription [49]
and in Alzheimer’s disease [50] are available. Here we
review the recent studies indicating that Pin1 plays an
important role in breast development and cancer and
could be an attractive new target for breast cancer treat-
ment.
Pin1 in breast development
The mammary gland undergoes a sequence of dynamic
changes throughout the female life cycle, especially during
pregnancy. These developmental changes depend on the
responsiveness of the mammary epithelial cells to hor-
mones and growth factors and on the activation of various
intracellular signaling pathways [51–53].
We observed that Pin1 knockout mice display a develop-
mental defect during pregnancy in preparation for lacta-
tion [37]. Before pregnancy, the mammary epithelial ducts
from both wild-type and Pin1–/– female mice develop nor-
mally. These results indicate that Pin1 is not required for
the development of the primary mammary tree, but rather
is required for the rapid and timely expansion of mammary
epithelial compartment in preparation for lactation. During
pregnancy, the mammary epithelial ducts rapidly extend
their side branches and build up alveoli, which replace the
mammary fat pad and form lobules in preparation for lacta-
tion. Pin1–/– female mice, however, show severely reduced
mammary epithelial duct development during pregnancy,
and the mammary gland fails to undergo the usual massive
expansion [37]. This phenotype in the Pin1 knockout
mouse is strongly reminiscent of the phenotype resulting
from the deletion of cyclin D1, which has a well-estab-
lished role in the development of breast epithelial cells
[54,55]. Consistently, protein levels of cyclin D1 are
decreased in mammary epithelial cells of Pin1 knock-out
mice [37]. These results indicate that Pin1 plays an impor-
tant role in breast development, probably via regulation of
cyclin D1 function. This conclusion has been indepen-
dently supported by various studies linking Pin1 to cyclin
D1 and breast cancer, as described below.
Pin1 in breast cancer
Overexpression of Pin1 in human breast cancer
Given that Pin1 regulates the conformation of certain phos-
phorylated Ser/Thr-Pro motifs — the critical motifs in breast
cancer — an interesting question is whether Pin1 expression
is aberrantly regulated in human breast cancer. Indeed, strik-
ing differences have been found in the levels of expression of
Pin1 protein in normal and primary human breast cancer
tissues [34]. In this study, Pin1 was overexpressed in 71% of
grade II tumors and 90% of grade III tumors. Although there
were considerable interindividual variations, especially in
grade II and III tumors, the mean expression level of Pin1 in
cancer samples was about 10 times that in normal controls.
Pin1 levels positively correlate with the tumor grade in inva-
sive breast cancer. In addition, its levels were considerably
higher in cell lines derived from human breast cancers than
in either normal mammary epithelial cells or cell lines estab-
lished from such cells [34]. It can be concluded that Pin1 is
overexpressed in human breast cancer.
One of the exciting findings from analyzing Pin1 expression
in human breast cancer is that levels of this isomerase sig-
nificantly correlate with cyclin D1 and β-catenin [34,35],
two strong and independent prognostic factors for human
breast cancer [8,56–58]. In confirmation of previous
reports [12,13], in the study cited above cyclin D1 was
overexpressed in about 50% of patient samples (24 of the
51) [34]. Of these tumors overexpressing cyclin D1, over
80% also had high levels of Pin1, on average twice as high
as in cyclin-D1-negative tumors. Furthermore, there is a link
between Pin1 overexpression and cyclin D1 transcription,
as all but one patient with high cyclin D1 mRNA levels also
had high Pin1 levels, while a few patients had high Pin1 but
low cyclin D1 mRNA levels [34].
There is also a strong correlation between Pin1 expres-
sion and the level and subcellular localization of β-catenin
[35]. Both Pin1 and β-catenin are highly overexpressed in
breast cancer tissues in comparison with normal tissues,
with the levels of Pin1 significantly correlating with those
of  β-catenin [35]. Moreover, in tumor tissues with high
levels of Pin1, β-catenin accumulates in the nuclear/cyto-
plasmic fraction, whereas in tumor tissues containing low
levels of Pin1, β-catenin is primarily localized at mem-
branes [35]. Given the prognostic value of cyclin D1 levels
and the nuclear/cytoplasmic fraction of β-catenin in breast
cancer [8,56–58], Pin1 expression is a new potential
prognostic marker for breast cancer.78
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Among other breast cancer markers there is a trend
towards a correlation of Pin1 with Neu/ErbB2/Her2 or
estrogen receptor negative status. But this did not reach
statistical significance, probably because of the small
number of estrogen-receptor-negative and/or Her2/Neu-
positive patients in the study [34]. It is of interest, however,
that the mean Pin1 levels in estrogen-receptor-negative
patients and in Her2/Neu-positive patients are, respec-
tively, about twice and 1.7 times those in normal controls
[34]. Further studies in larger cohorts may clarify the rela-
tion of Pin1 expression to these unfavorable biochemical
markers and establish whether Pin1 expression in itself is a
useful additional marker for breast cancer prognosis.
Mechanisms of Pin1 overexpression in breast cancer
The causes of elevated Pin1 levels in human breast
cancer samples are not fully clear. Given that the cyclin
D1 gene is amplified in 10–15% of breast cancers [59], it
would be interesting to determine whether Pin1 overex-
pression is due to any genetic alterations. However, the
Pin1 gene is one of those that are most drastically sup-
pressed by up-regulation of BRCA1, as detected in cDNA
array screening and Northern analysis [60]. These results
suggest that Pin1 levels themselves are tightly regulated,
and that high Pin1 levels in cancer may be a result of
deregulation at the transcriptional or post-transcriptional
level. Indeed, findings in our laboratory indicate that Pin1
is tightly regulated at both the transcriptional and post-
transcriptional levels [36,61].
One of the transcriptional factors regulating Pin1 expres-
sion is E2F, which binds and activates the PIN1 promoter
in vitro and in vivo [36]. Furthermore, the binding of E2F1
to the PIN1 promoter in vivo was strongly correlated with
Pin1 expression in breast cancer cell lines [36]. Deregula-
tion of E2F/Rb pathways are observed in breast cancer
tissues and cell lines [1,62–66]. Therefore one might
speculate that deregulation of E2F plays a role in the up-
regulation of Pin1 protein levels in breast cancer.
In addition to transcriptional regulation, Pin1 is regulated
by phosphorylation, which fluctuates during the cell cycle
[61]. One of the Pin1 phosphorylation sites has been
mapped to Ser16 at the center of the shadow pSer/Thr-
Pro-binding pocket of the WW domain [61]. Phosphoryla-
tion of Ser16 would introduce a negatively charged
phosphate into the binding pocket and prevent the WW
domain from interacting with pSer/Thr-Pro motifs. Indeed,
phosphorylation of Ser16 completely abolishes the ability
of Pin1 to interact with its substrates and to carry out its
essential function in vivo [61]. Consistently, the dephos-
phorylated, presumably active, form of this isomerase is
accumulated in human breast cancer [34]. It would be
important to identify all its phosphorylation sites and their
functions, and to clone the protein kinases and phos-
phatases responsible for modulating its phosphorylation.
Role of Pin1 in the transformation of breast epithelial
cells
Given the overexpression of Pin1 in human breast cancer,
a critical question is whether this overexpression affects
some oncogenic pathways and/or contributes to the trans-
formation of breast epithelial cells. Of the many Pin1 sub-
strates identified so far [3], cyclin D1 is the most
extensively studied [34–37] and has a well-established
function in breast cancer [11–16]. Consistent with the
close correlation between Pin1 and cyclin D1 observed in
human breast cancer [34], Pin1 positively regulates cyclin
D1 function at the transcriptional level, in collaboration
with several different oncogenic signaling pathways and
also through post-translational stabilization [34,35,37].
Pin1 regulates expression of cyclin D1 in collaboration
with Ras and Wnt/β-catenin signaling pathways. Ras sig-
naling activates the mitogen-activated protein kinase c-Jun
N-terminal kinases, which phosphorylate c-Jun on two crit-
ical amino terminal Ser-Pro motifs (S63/73-P) thereby
enhancing its transcriptional activity [7,14,54,55,67–75].
Pin1 binds c-Jun phosphorylated on Ser 63 and 73, and
also increases its ability to activate the cyclin D1 promoter
in cooperation either with activated c-Jun N-terminal
kinase or oncogenic Ha-Ras [34]. Activation of the Wnt/β-
catenin signaling pathway is another mechanism leading
to cyclin D1 activation and a major feature of breast
cancer [8,76–78]. Pin1 binds exclusively to phosphory-
lated  β-catenin close to the APC interaction site. APC
(adenomatous polyposis coli [protein]) is a nuclear–cyto-
plasmic shuttling protein that can export nuclear β-catenin
to the cytoplasm for degradation [35]. Pin1 binds and iso-
merizes the pSer246–Pro peptide bond in β-catenin, which
inhibits its ability to bind APC, thereby stabilizing β-catenin
and causing its nuclear accumulation [35].
In addition, Pin1 can bind and stabilize cyclin D1 protein
[37]. Phosphorylation of cyclin D1 by GSK-3β (glycogen
synthase kinase 3 beta) on the Thr286-Pro site regulates
turnover and localization of cyclin D1 by enhancing its
binding to the nuclear transporter CRM1 and nuclear
export, which leads to degradation of cyclin D1 in the
nucleus [9,10]. Pin1 binds and stabilizes phosphorylated
cyclin D1, presumably by preventing its nuclear export and
proteolysis in cytoplasm [37]. Thus, Pin1 positively regu-
lates cyclin D1 function at both transcriptional and post-
translational levels, and this may explain why loss of Pin1
function in the mouse mimics the cyclin-D1-null pheno-
types [37].
Recent data support the notion that Pin1 can partially
transform mammary epithelial cells [36]. Overexpression
of Pin1 can confer anchorage-independent cell growth to
MCF-10A cells, a spontaneously immortalized, but non-
transformed, mammary epithelial cell line [36,79,80]. Fur-
thermore, MCF-10A cells overexpressing Pin1 fail to79
undergo normal cell differentiation and acinal formation
when cultured in three-dimensional matrigel, with the phe-
notype consistent with early transformation [36,80].
However, Pin1 overexpression seems not to affect cell
growth or cell morphology under normal growth condi-
tions [36]. It is possible that Pin1 becomes oncogenic
only after activation of some other oncogenic pathways
leading to phosphorylation of its substrates. Indeed, Pin1
greatly enhances and facilitates transformation induced by
oncogenic Neu and Ras in mammary epithelial cells [36].
In contrast, inhibition of Pin1 inhibits both cell proliferation
and the transformed phenotypes induced by Neu/Ras
oncogenes [36]. Importantly, these transformed pheno-
types suppressed by inhibition of Pin1 can be fully
rescued by overexpression of a constitutively active cyclin
D1 mutant that is refractory to the Pin1 inhibition [36].
These results indicate that Pin1 is essential for the
Neu/Ras-induced transformation of mammary epithelial
cells and that cyclin D1 is the major target of Pin1 during
this transformation.
On the basis of these results, we propose that Pin1,
whose expression is activated by oncogenic pathways,
can cooperate with oncogenic pathways in a ‘post-phos-
phorylational’ regulation where the prompt cis–trans iso-
merization of prolyl residues adjacent to phosphorylated
serine or threonine residues promotes cell proliferation
and transformation. In this model, Pin1 is an indispensable
translator and amplifier of oncogenic signal transduction,
which responds to oncogenic signaling and translates it
into cell proliferation and transformation.
Pin1 as a new drug target for breast cancer treatment
In the past several years, the signal transduction cascades
have become promising targets for anticancer therapy,
especially breast cancer therapy [81–83]. For example,
trastuzumab (Herceptin), the monoclonal antibody against
Her2/Neu/ErbB2, is now part of the standard armamentar-
ium in treating metastatic breast cancer, and studies are
under way to evaluate its use in adjuvant treatment
[84,85]. Flavopiridol is a potent inhibitor of cell division
protein kinases (Cdks), especially Cdk4, a key enzyme in
the cyclin D1/Rb pathway, and is being evaluated in phase
II trials. In preclinical studies, the combination of Flavopiri-
dol and Herceptin has shown synergistic activity in block-
ing downstream signaling and cyclin D1 activation [86].
ZD1839 (Iressa) is a selective inhibitor of the epidermal
growth factor receptor tyrosine kinase, with substantial
clinical activity in a number of adenocarcinomas. Interest-
ingly, tumors positive for Her2/neu are especially sensitive
to Iressa, and in vitro Iressa and Herceptin have consider-
able synergistic anticancer activity [87,88]. Finally, the
function of Ras can be inhibited by blocking its post-tran-
scriptional farnesylation, and the efficacy of Ras farnesyla-
tion inhibitors (such as tipifarnib) is now being evaluated in
clinical trials [89].
Because of its overexpression and its pivotal role at the
multiple steps during various oncogenic activation path-
ways in breast cancer [34–37], Pin1 may become an
appealing drug target for breast cancer therapy. Inhibition
of Pin1 would block activation of cyclin D1 through multi-
ple mechanisms [34–37]. Since the absence of cyclin D1
has been shown to protect mice from breast cancers
induced by Ras or Her2/Neu [16], the inhibition of Pin1
might be similarly protective. Furthermore, even partial
inhibition of Pin1 appears to be sufficient to suppress the
transformed phenotype of breast epithelial cells, while it
might not be generally toxic [36]. The idea that Pin1
depletion is conceivably not generally toxic is supported
by the Pin1-null phenotype in mice, which is viable and
displays very specific abnormalities only after a long time
without Pin1 [31,35,37]. This idea is further supported by
the findings that suppression of Neu- and Ras-induced
transformed phenotypes by Pin1 inhibition can be rescued
by overexpression of a constitutively active cyclin D1
mutant that is refractory to the Pin1 inhibition [36].
Although Pin1 inhibition with antisense strategies and
dominant-negative mutants has been employed success-
fully in vitro [17,36,61,90], the feasibility of therapeutic
Pin1 inhibition has not yet been explored. An active yet
nonspecific PPIase inhibitor is the naturally occurring
naphthoquinone derivative juglone [91]. This derivative
covalently inactivates a unique cysteine in the active site of
the third family of PPIases, including Pin1-type and
parvulin-type PPIases [91]. Juglone has been shown to
have some anticancer activity and has been used as a
Pin1 inhibitor in some studies in cells [90,92,93].
However, since juglone has been shown to inhibit many
other proteins and enzymes, even some with a much
higher potency than Pin1 [92,94–96], its metabolic
effects are clearly not restricted to PPIase inhibition.
Therefore, there is a need for the development of highly
Pin1-specific inhibitors. The development of such specific
inhibitors with a favorable toxicity profile may open up new
treatment options for breast cancer. They could be effica-
cious in themselves or in combination with either classic
chemotherapy or other molecularly targeted anticancer
drugs aimed at disrupting Her2/Neu or Ras signaling.
Role of Pin1 in other cell types and cancers
Various studies suggest that Pin1 might also play an
important role in many other cell types and cancers,
besides its role in breast development and breast cancer.
Following the original identification of the human Pin1 as a
protein that is able to interact with and suppress a mitotic
kinase [17], subsequent studies have confirmed that Pin1
is a critical mitotic regulator that modulates the function of
many mitotically phosphorylated proteins [18,23,25,
28–30]. Further studies indicate that Pin1 also plays a
critical role in other cell cycle transition points, notably the
G1/S transition by modulating some key G1/S regulators
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such as cyclin D1 and its upstream regulators [34–37], as
well as cell cycle checkpoint regulation induced by inhibit-
ing DNA synthesis [32] or damaging DNA [45–47].
Consistent with the important roles of Pin1 in the cell
cycle, its expression varies greatly among different tissues
and cell types in both humans [26,34,35] and mice [37].
Readily detectable levels of Pin1 are generally seen in
rapidly proliferating cells such as the urothelium and the
epithelial cells located at the bottom of colon crypts
[34,37]. Furthermore, loss of Pin1 function in the mouse
causes a range of abnormalities due to defective cell pro-
liferation and differentiation. These include decreased
body size, testicular atrophy, and retinal degeneration, in
addition to defects in breast epithelial cells [37]. However,
not all rapidly dividing normal cells or tumors are Pin1-pos-
itive [34,35], and some nondividing neurons in humans
[26] and mice [37] also express Pin1. Therefore, this iso-
merase is probably not a general proliferative marker and
may have different functions in nondividing and dividing
cells [34,35,37]. It is specifically overexpressed in a
number of human adenocarcinomas such as colon,
prostate, and lung cancer, and in sarcomas such as lym-
phoma and melanoma [34,35]. In contrast, inhibition of the
Pin1 function in multiple human cancer cell lines using
expression of a Pin1 antisense RNA or dominant-negative
mutants induces mitotic arrest and apoptosis [17,61,90].
These various findings indicate that Pin1 probably plays
an important and specific role in regulating cell prolifera-
tion under physiological and oncogenic conditions.
Further experiments are required to elucidate its biological
functions and underlying molecular mechanisms in differ-
ent cell types and to determine the significance of its over-
expression in the development, diagnosis, prognosis, and
treatment of various human cancers.
Conclusion
Recent studies indicate that phosphorylation-dependent
prolyl isomerization is a new post-phosphorylation signal-
ing mechanism that plays an important role in diverse cel-
lular processes. Importantly, this mechanism has provided
new insights into breast development and cancer. Pin1 is
overexpressed in breast cancer and may function to trans-
late or amplify multiple oncogenic signaling mechanisms
during oncogenesis. In contrast, inhibition of Pin1 could
provide a unique way of disrupting oncogenic pathways
and therefore represent an appealing target for anticancer
therapies. A major challenge for the future will be to
develop various animal models to further elucidate the
molecular mechanisms by which Pin1 regulates breast
development and cancer and to define the interactions
between Pin1 and other oncogenes or tumor suppressors
involved in breast cancer. Another major challenge will be
to develop Pin1-specific inhibitors and to evaluate their
potential for treating breast cancer.
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